MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism
December 02, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
November 18, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 07, 2024 08:00 ET
|
MBX Biosciences, Inc.
Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject last visit in Phase 1 trial of MBX 1416 anticipated by late November;...
MBX Biosciences to Participate in Upcoming November Investor Conferences
October 28, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
September 30, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 16, 2024 16:05 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
MBX Biosciences Announces Pricing of Initial Public Offering
September 12, 2024 19:11 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
MBX Biosciences Announces Launch of Initial Public Offering
September 09, 2024 06:30 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision...
MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
August 12, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Aug. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...